Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 4979 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2013  |  Volume : 17  |  Issue : 2  |  Page : 245-248

New options for the medical treatment of Cushing's syndrome

Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, United Kingdom

Correspondence Address:
Peter J Trainer
Department of Endocrinology, The Christie NHS Foundation Trust, Manchester
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.109685

Rights and Permissions

A number of drugs have been advocated for the medical management of Cushing's syndrome but few have gained widespread acceptance. The most reliably effective agents are metyrapone and ketoconazole as monotherapy, or in combination. Cabergoline may be of value in a minority of patients but pasireotide is a more reliable and effective agent that lowers cortisol secretion in the great majority of patients, although only normalises UFC in a minority. The potential for combination of an agent that blocks adrenal steroidogenesis with inhibition of ACTH secretion by pasireotide needs to be explored.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded679    
    Comments [Add]    
    Cited by others 4    

Recommend this journal